|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||||
| Investments at fair value | |||||||||||||||||
| Non-controlled/non-affiliated investments | |||||||||||||||||
| Non-controlled/affiliated investments | |||||||||||||||||
| Total investments at fair value | |||||||||||||||||
| Cash and Cash Equivalent | |||||||||||||||||
| Interest receivable from non-controlled/non-affiliated investments | |||||||||||||||||
| Non-controlled/non-affiliated investments | |||||||||||||||||
| Non-controlled/affiliated investments | |||||||||||||||||
| Receivable from broker | |||||||||||||||||
| Deferred financing costs | |||||||||||||||||
| Receivable for investments | |||||||||||||||||
| Receivable for shares sold | |||||||||||||||||
| Derivative assets at fair value (Note 6) | |||||||||||||||||
| Total assets | |||||||||||||||||
| LIABILITIES | |||||||||||||||||
| Debt (net of unamortized debt issuance costs of $46,470 and $39,900, respectively) | |||||||||||||||||
| Payable for investments | |||||||||||||||||
| Due to affiliates | |||||||||||||||||
| Management fees payable (Note 3) | |||||||||||||||||
| Income based incentive fees payable (Note 3) | |||||||||||||||||
| Capital gains based incentive fees payable (Note 3) | |||||||||||||||||
| Interest payable | |||||||||||||||||
| Derivative liabilities at fair value (Note 6) | |||||||||||||||||
| Distribution payable | |||||||||||||||||
| Board of Trustees’ fees payable | |||||||||||||||||
| Accrued expenses and other liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| NET ASSETS | |||||||||||||||||
| Common Shares, $0.001 par value (unlimited shares authorized; 232,970,063 and 231,969,058 shares issued and outstanding, respectively) | |||||||||||||||||
| Additional paid in capital | |||||||||||||||||
| Distributable earnings (loss) | |||||||||||||||||
| Total net assets | |||||||||||||||||
| Total liabilities and net assets | |||||||||||||||||
| NET ASSET VALUE PER SHARE (in usd per share) | |||||||||||||||||
Loading...